Multicenter Study of Secukinumab Uptitration in Axial Spondyloarthritis: Real-World Evidence
SEC uptitration to 300 mg was associated with sustained improvements in disease activity and favorable retention and safety in axSpA patients with active disease after receiving SEC 150 mg, supporting dose escalation as a clinically effective and safe strategy.
Authors
- A. Gallego
- C. Arconada
- R. López-Sánchez (ORCID: https://orcid.org/0000-0002-6200-1397)
- Isabel de la Morena Barrio
- Álvaro García Martos (ORCID: https://orcid.org/0000-0003-0433-0341)
- A. García-Valle
- A. García Dorta (ORCID: https://orcid.org/0000-0003-1820-9630)
- D. Freites (ORCID: https://orcid.org/0000-0002-0966-2778)
- Cristina Valero (ORCID: https://orcid.org/0000-0003-2013-1545)
- Manuel Gómez
- Manuel Fernández-Prada
- Antonio Álvarez de Cienfuegos
- Marta Valero Expósito
Institutions
- Hospital Universitario de Canarias (ES)
- Hospital Clínico San Carlos (ES)
- Hospital Universitario de Guadalajara (ES)
- Hospital Clínico Universitario de Valencia (ES)
- Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (ES)
- Hospital Universitario de Gran Canaria Doctor Negrín (ES)
- Hospital Universitario del Tajo (ES)
- Hospital Universitario Araba (ES)
- Hospital Universitario de La Princesa (ES)
- Centro de Implantología Cirugía Oral y Maxilofacial (ES)
- Hospital Vega Baja (ES)
- Hospital Universitario Ramón y Cajal (ES)
- Complejo Asistencial Universitario de Palencia (ES)
- Hospital Universitario Infanta Leonor (ES)
Publication Details
- Journal
- The Journal of Rheumatology
- Published
- 2025-10-15
- DOI
- https://doi.org/10.3899/jrheum.2025-0102
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00